Cancer

Ellipses Pharma Cleared by FDA to Open Phase I/II AML Trial

Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology

Amgen's Lumakras Sales Increased 58 Percent in Q4 2022

Coeptis Therapeutics, University of Pittsburgh Studying SNAP-CAR Therapy in HER2-Positive Cancers

Aptose Biosciences Begins Expansion Trial of Tuspetinib in TP53, FLT3-Mutant AML

International Commission to Expand Molecular Testing Access for Cancer Patients

NYU Langone Perlmutter Cancer Center to Validate Biological Dynamics Pancreatic Cancer Test

Guardant Health to Integrate Lunit's AI PD-L1 Scoring Algorithm Into Tissue Test Offering

Arima Genomics to Offer NGS-Based Gene Fusion Test Through Protean BioDiagnostics CLIA Lab

C4 Therapeutics Begins Phase I/II Trial of Protein Degrader in BRAF V600-Mutant Solid Tumors

Daiichi Sankyo, AstraZeneca Begin Phase III Trial of TROP2 Inhibitor, Keytruda in NSCLC

Menarini's Orserdu, Guardant's ctDNA CDx Net FDA Approval for ESR1-Mutated Breast Cancer Patients

Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody

Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial

In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck

NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients

BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data